{
    "id": 29555,
    "fullName": "EPHA2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EPHA2 positive indicates the presence of the EPHA2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1969,
        "geneSymbol": "EPHA2",
        "terms": [
            "EPHA2",
            "ARCC2",
            "CTPA",
            "CTPP1",
            "CTRCT6",
            "ECK"
        ]
    },
    "variant": "positive",
    "createDate": "03/14/2019",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16367,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BT5528 treatment resulted in tumor regression in cell line xenograft models of Epha2-positive fibrosarcoma (Cancer Res 2018;78(13 Suppl):Abstract nr 5854).",
            "molecularProfile": {
                "id": 31613,
                "profileName": "EPHA2 positive"
            },
            "therapy": {
                "id": 8009,
                "therapyName": "BT5528",
                "synonyms": null
            },
            "indication": {
                "id": 3355,
                "name": "fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14469,
                    "pubMedId": null,
                    "title": "BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/5854"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16368,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BT5528 treatment resulted in tumor regression in cell line xenograft models of Epha2-positive triple-receptor negative breast cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 5854).",
            "molecularProfile": {
                "id": 31613,
                "profileName": "EPHA2 positive"
            },
            "therapy": {
                "id": 8009,
                "therapyName": "BT5528",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14469,
                    "pubMedId": null,
                    "title": "BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/5854"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16369,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BT5528 treatment resulted in tumor regression in cell line and patient-derived xenograft (PDX) models of Epha2-positive non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 5854).",
            "molecularProfile": {
                "id": 31613,
                "profileName": "EPHA2 positive"
            },
            "therapy": {
                "id": 8009,
                "therapyName": "BT5528",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14469,
                    "pubMedId": null,
                    "title": "BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/5854"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31613,
            "profileName": "EPHA2 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}